WELCOME TO The Biotechnology REPORT
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
NiKang Therapeutics | May 31, 2021
NiKang Therapeutics Inc., a clinical-stage biotech company focused on developing innovative small molecule oncology medicines to assist patients with unmet medical needs; today announced the completion of an oversubscribed $200 million Series C financing led by Cormorant Asset Management, HBM Healthcare Investments, and Octagon Capital Advisors with participation from a premier syndicate of funds, including new investors EcoR1 Capital, Perceptive Advisors, Wellington Management, Ally Bridge Grou...
Cell and Gene Therapy
Thermo Fisher Scientific | March 01, 2021
Thermo Fisher Scientific Inc. (NYSE: TMO), the world chief in serving science, today reported it has finished its recently declared obtaining of Mesa Biotech, Inc., a secretly held purpose of-care sub-atomic analytic organization.
Plateau Biotech has built up the Accula System, a moderate, simple to-utilize, purpose of-care PCR-based testing stage for irresistible infection conclusion. The stage empowers fast, exceptionally precise testing at doctor workplaces, drug stores and dif...
Nanoform | November 27, 2020
Nanoform Finland Plc ("Nanoform"), an innovative nanoparticle medication empowering organization, today reported a proprietary technology that can frame biological nanoparticles as small as 50 nm and declared another close term business focus for 2021 to convey its first biologics Proof of Concept project for this new technology with a pharmaceutical or biotech partner.
As drug molecules become more complex so do the alternatives to convey them. This complex nanoparticle...
Clover Biopharmaceuticals | February 25, 2022
Clover Biopharmaceuticals, Ltd. a global clinical-stage biotechnology company developing novel vaccines and biologic therapeutic candidates, today announced that it has been selected for inclusion in the Hang Seng Composite Index as a constituent stock, effective March 7, 2022.
Hang Seng Composite Index
Hang Seng Small Cap (Investable) Index
Hang Seng Healthcare Index
Hang Seng Hong Kong-Listed Biotech Index
Cell and Gene Therapy, Industrial Impact
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE